Skip to main content
OpenTrials

Clinical trial condition

Carcinoma, Squamous Cell

Explore clinical trials studying Carcinoma, Squamous Cell. Study availability and eligibility vary by location and protocol.

1,631 public trials 441 recruiting studies
Refine in advanced search Browse all conditions

Carcinoma, Squamous Cell trial results

Recruiting

A Study of JNJ-90301900 in Combination With Chemoradiation Therapy in Participants With Locally Advanced Head and Neck Squamous Cell Carcinoma

NCT07219212

Conditions
Carcinoma, Carcinoma, Squamous Cell, Head and Neck Neoplasms, +5 more
Locations
  • University of Alabama at Birmingham Birmingham, Alabama, United States
  • City of Hope Duarte, California, United States
  • Mayo Clinic Jacksonville, Florida, United States
  • Moffit Cancer center Tampa, Florida, United States
View all 17 locations
View Trial Details
Recruiting

A Study of BMS-986340 as Monotherapy and as Combination Therapy in Participants With Advanced Solid Tumors

NCT04895709

Conditions
Adenocarcinoma, Adnexal Diseases, Breast Diseases, +56 more
Locations
  • Community Cancer Institute Clovis, California, United States
  • USC/Norris Comprehensive Cancer Center Los Angeles, California, United States
  • Hoag Memorial Hospital Presbyterian Newport Beach, California, United States
  • University of Iowa Iowa City, Iowa, United States
View all 47 locations
View Trial Details
Recruiting

A Study to Investigate ALE.P02 as Monotherapy in Adult Patients With Selected CLDN1+ Solid Tumors

NCT06747585

Conditions
Carcinoma, Carcinoma, Squamous Cell, Cervical Squamous Cell Carcinoma, +16 more
Locations
  • Mayo Foundation for Medical Education and Research - Mayo Cl Scottsdale, Arizona, United States
  • Providence Medical Foundation Fullerton, California, United States
  • USC Norris Comprehensive Cancer Center Los Angeles, California, United States
  • Yale Comprehensive Cancer Center New Haven, Connecticut, United States
View all 41 locations
View Trial Details
Recruiting

A Study to Evaluate Investigational Agents With or Without Pembrolizumab (MK-3475) in Participants With Advanced Esophageal Cancer Previously Exposed to Programmed Cell Death 1 Protein (PD-1)/ Programmed Cell Death Ligand 1 (PD-L1) Treatment (MK-3475-06B)

NCT05319730

Conditions
Carcinoma, Carcinoma, Squamous Cell, Digestive System Diseases, +13 more
Locations
  • University of Arizona Cancer Center-University of Arizona Cancer Center ( Site 4927) Tucson, Arizona, United States
  • UCLA Hematology/Oncology - Santa Monica ( Site 4905) Los Angeles, California, United States
  • Hematology-Oncology Associates of Central NY, P.C. ( Site 4925) East Syracuse, New York, United States
  • Columbia University Irving Medical Center-CUIMC Herbert Irving Comprehensive Cancer Center Clinical ( Site 4907) New York, United States
View all 59 locations
View Trial Details
Recruiting

Testing the Addition of the Drug BMX-001, a Radioprotector, or a Placebo to the Usual Chemoradiation Therapy for Patients With Head and Neck Cancer

NCT06532279

Conditions
Carcinoma, Carcinoma, Squamous Cell, Clinical Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, +62 more
Locations
  • Arizona Center for Cancer Care - Gilbert Gilbert, Arizona, United States
  • Arizona Center for Cancer Care-Peoria Peoria, Arizona, United States
  • Arizona Center for Cancer Care - Phoenix Phoenix, Arizona, United States
  • Arizona Center for Cancer Care - Scottsdale Scottsdale, Arizona, United States
View all 153 locations
View Trial Details
Recruiting

Comparing Sentinel Lymph Node (SLN) Biopsy With Standard Neck Dissection for Patients With Early-Stage Oral Cavity Cancer

NCT04333537

Conditions
Buccal Mucosa Squamous Cell Carcinoma, Carcinoma, Carcinoma, Squamous Cell, +20 more
Locations
  • University of Alabama at Birmingham Cancer Center Birmingham, Alabama, United States
  • Banner MD Anderson Cancer Center Gilbert, Arizona, United States
  • Mayo Clinic Hospital in Arizona Phoenix, Arizona, United States
  • Banner University Medical Center - Tucson Tucson, Arizona, United States
View all 107 locations
View Trial Details
Recruiting

Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma and Other Solid Tumors, Receiving Intravenous Infusion of Azirkitug Alone or in Combination(s) With Budigalimab, Bevacizumab, or Telisotuzumab Adizutecan

NCT05005403

Conditions
Anophthalmia with pulmonary hypoplasia, Breast Diseases, Breast Neoplasms, +38 more
Locations
  • City of Hope National Medical Center /ID# 276272 Duarte, California, United States
  • City of Hope - Orange County Lennar Foundation Cancer Center /ID# 278589 Irvine, California, United States
  • USC Norris Comprehensive Cancer Center /ID# 279603 Los Angeles, California, United States
  • University of Illinois Hospital and Health Sciences System /ID# 251750 Chicago, Illinois, United States
View all 48 locations
View Trial Details

Related conditions